Advances in molecular biology and genomics have significantly improved understanding of neuroblastoma pathogenesis, revealing the critical role of genetic and epigenetic alterations-such as <i>MYCN</i> amplification, <i>ALK</i> mutations, and chromosomal aberrations-in disease behavior and prognosis. The gene discussed is MYCN; the disease is neuroblastoma.